I. Concepts.- 1. Pharmacologic control of specific gene expression.- 2. Modulation of the activity of cancer chemotherapeutic agents by dipyridamole.- II. New drugs and modifiers.- 3. Pharmacology and clinical investigation of SR-2508 (etanidazole).- 4. Folate antimetabolites inhibitory to de novo purine synthesis.- 5. Taxol: A new agent active in melanoma and ovarian cancer.- 6. ICRF-187 (ADR-529) cardioprotection against anthracycline-induced cardiotoxicity: Clinical and preclinical studies.- 7. Uroprotection in patients receiving cyclophosphamide and ifosfamide.- III. Disease targets.- 8. The role of progesterone receptors in meningioma.- 9. Combined chemotherapy and radiotherapy in small-cell lung cancer.- Addendum to Chapter 2.Springer Book Archives